by Tanya B. Dorff, MD; Robert Dreicer, MD, MS, MACP, FASCO; and Neal D. Shore, MD, FACS
With multiple treatments now available for advanced prostate cancer, there are many options for the sequencing of therapies. Our featured experts e......READ MORE
by Tanya B. Dorff, MD; Robert Dreicer, MD, MS, MACP, FASCO; and Neal D. Shore, MD, FACS
Molecular and genomic tests have the potential to add key prognostic data to the assessment of earlier-stage prostate cancer. Ongoing trials seek t......READ MORE
Combination strategies have led to improved survival in patients with advanced prostate cancer. Researchers hope to build on this success by implem......READ MORE
Barriers seem to persist in the adoption of the standard of care in metastatic castration-sensitive prostate cancer (mCSPC). All contemporary oncol......READ MORE
Our featured expert notes the importance of ensuring that the patient's voice is being heard throughout the development of clinical trial designs. ......READ MORE
Prostate-specific membrane antigen positron emission tomography (PSMA PET) continues to be widely adopted. Clinical trials including both PSMA PET ......READ MORE
